PROSTASCINT Drug Profile

Summary for Tradename: PROSTASCINT

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for PROSTASCINT

Recent Clinical Trials for PROSTASCINT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Molecular Insight Pharmaceuticals, Inc.	Phase 1
National Cancer Institute (NCI)	Phase 2
David M. Schuster, MD	Phase 2

See all PROSTASCINT clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROSTASCINT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROSTASCINT Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PROSTASCINT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608		2036-08-10	Patent claims search
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608		2036-02-23	Patent claims search
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608		2037-01-25	Patent claims search
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608		2039-11-20	Patent claims search
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608		2039-11-22	Patent claims search

Market Dynamics and Financial Trajectory for PROSTASCINT

Last updated: April 12, 2026

What is PROSTASCINT and its Current Market Status?

PROSTASCINT (capromab pendetide) is a monoclonal antibody-based radiopharmaceutical designed for imaging prostate cancer. It was developed by Cytograft Tissue Engineering and licensed to diCE Pharmaceuticals. The drug is intended to detect prostate-specific membrane antigen (PSMA) expression in prostate adenocarcinoma tissues. Approved by the U.S. Food and Drug Administration (FDA) in 1999, PROSTASCINT's FDA approval was for positron emission tomography (PET) imaging of prostate cancer recurrence.

However, it currently has limited commercial presence due to market, regulatory, and technological shifts. Its market existence is primarily in niche diagnostic uses within specific institutions.

What Are the Key Market Drivers and Barriers?

Market Drivers

• Growing prostate cancer prevalence: Estimated to reach 248,530 new cases in the U.S. in 2021, driving demand for accurate diagnosis tools[1].
• Demand for advanced imaging: Increased adoption of PET imaging for cancer staging supports niche diagnostics like PROSTASCINT.
• Limited competition in niche use cases: Other PSMA-targeted imaging agents, such as 68Ga-PSMA-11 and 18F-DCFPyL, increase the relevance of existing options for prostate cancer detection.

Market Barriers

• Technological obsolescence: The advent of newer, more sensitive PET radiotracers limits PROSTASCINT’s use.
• Regulatory and reimbursement challenges: Difficulty securing coverage and reimbursement reduces market access.
• Operational complexity: Radioimmunoassay and particular storage/handling requirements hinder broad adoption.
• Market dominance of newer agents: FDA-approved PET tracers specializing in prostate cancer detection have captured most of the market share since 2017.

How Has the Market Evolved?

Historical Market Context

• FDA approval in 1999; initial adoption was limited due to the complexity and cost of use.
• Market stagnation post-2005, as newer PET imaging agents were developed.
• Renewed interest in niche applications, primarily in academic and specialized clinical settings.

Recent Market Trends

• The global prostate cancer imaging drugs market valued at approximately USD 180 million in 2020, with expected CAGR of 6.2% from 2021 to 2028[2].
• The emergence of PSMA-based PET imaging agents has reduced the prominence of PROSTASCINT.
• US payers show limited reimbursement for PROSTASCINT, constraining its market penetration.

What Is the Financial Trajectory?

Revenue and Sales Estimates

• Estimated peak annual revenue of USD 10–20 million during initial years post-approval (late 1990s to early 2000s).
• Current sales are negligible, estimated below USD 1 million annually.
• Limited global sales due to regulatory constraints and market shifts.

Investment and Development Costs

• R&D and regulatory compliance costs for PROSTASCINT are unrecoverable, given its current niche status.
• Potential repurposing or modernization would require significant capital, estimated at USD 50–100 million for development, regulatory approval, and market re-entry.

Future Financial Outlook

• The drug’s market size is expected to decline further with the adoption of next-generation PSMA PET agents.
• Use is confined largely to retrospective studies or specific institutional applications.
• No significant pipeline modifications or planned regulatory reopenings are publicly announced.

How Do Competitive Alternatives Impact Its Market?

Agent	Type	Approved Use	Market Share (2022)	Limitations
68Ga-PSMA-11	PET radiotracer	Prostate cancer detection	Dominates niche clinical settings	Short half-life, limited availability
18F-DCFPyL	PET radiotracer	Prostate cancer detection	Expanding use	Costlier manufacturing process

These agents outperform PROSTASCINT in sensitivity, specificity, and operational convenience, shrinking its relevance.

Conclusion

PROSTASCINT's market existence is limited to specialized diagnostic applications. It faces competition from advanced PET radiotracers that dominate the prostate cancer imaging landscape. Its financial trajectory indicates near-zero growth, with existing revenues constrained by technological obsolescence and reimbursement hurdles. Any expansion would depend on regulatory reforms or new clinical indications, which appear unlikely without substantial re-adaptation.

Key Takeaways

• PROSTASCINT is an FDA-approved imaging agent for prostate cancer recurrence but has minimal current market activity.
• It has been largely supplanted by newer PSMA-targeted PET agents offering better sensitivity and operational features.
• The global prostate cancer imaging market is growing, but PROSTASCINT's niche status limits its share.
• Future revenues are unlikely to recover without significant investment in modernization or new indications.
• Competitive pressures strongly favor advanced PET radiotracers over PROSTASCINT.

FAQs

1. Can PROSTASCINT be used for primary prostate cancer detection?
No. Its FDA approval specified use in prostate cancer recurrence imaging, not primary detection.

2. Are there plans to redesign or relaunch PROSTASCINT?
Publicly available information indicates no active plans for redesign or relaunch initiatives.

3. How does PROSTASCINT compare to newer PSMA PET agents?
It has lower sensitivity, limited operational convenience, and less favorable reimbursement profiles.

4. Is PROSTASCINT covered by Medicare or private insurers?
Coverage is scarce; reimbursement challenges restrict its clinical use.

5. What alternative diagnostic tools are replacing PROSTASCINT?
68Ga-PSMA-11 and 18F-DCFPyL PET tracers dominate current clinical practice.

References

[1] American Cancer Society. (2021). Cancer Facts & Figures 2021.
[2] MarketsandMarkets. (2021). Prostate Cancer Imaging Market by Product & Service, Application, End User – Global Forecast to 2028.